1-6 of 6
Thomas Manley
Close
Sort by
Journal Articles

Novel CD123xCD3 Bispecific Igm Antibody, Igm-2537, Potently Induces T-Cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells In Vivo and in Vitro with Minimal Cytokine Release

Gene Li, Zhongde Ye, Poonam Yakkundi, Marigold Manlusoc, Kathryn Logronio, Leyla Tahrani, Rodnie Rosete, David Bernados, Paul Hinton, Deepal Pandya, Nardeen Hanna, Jey Anantam, Maya F Kotturi, Liz Bogaert, Jiyoung Hong, Christina Tsai, Thomas Manley, Bruce A Keyt, Angus M. Sinclair, Liqin Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4177.
https://doi.org/10.1182/blood-2023-182891
Published: 2023
Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Kerry J Savage, BSc, MD MSc, Steven M. Horwitz, MD, Ranjana H Advani, MD, Jacob H. Christensen, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, Franck Morschhauser, MD, Onder Alpdogan, MD, Cheolwon Suh, Kensei Tobinai, MD PhD, Andrei R Shustov, MD, Marek Trneny, MD prof, Sam Yuen, MBBS,FRCPA,FRACP, Pier Luigi Zinzani, MD PhD, Lorenz Truemper, MD, Timothy Illidge, MD PhD, Owen O'Connor, MD PhD, Barbara Pro, MD, Meredith Little, MPH, Veronica Bunn, Keenan Fenton, Thomas Manley, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 464.
https://doi.org/10.1182/blood-2019-122781
Published: 2019
Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 238.
https://doi.org/10.1182/blood-2019-122576
Published: 2019
Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Steven M. Horwitz, MD, Owen A. O'Connor, MD, PhD, Barbara Pro, MD, Tim M. Illidge, MDPhD, Michelle A. Fanale, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, MD PhD, Tatyana A. Feldman, MD, Anne Lennard, MBBS,FRCP, FRCPath, David Belada, MD PhD, Árpád Illés, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R. Shustov, MD, Andreas Hüttmann, MD, Kerry J Savage, BSc, MD MSc, Sam Yuen, Pier Luigi Zinzani, MD, Zhaowei Hua, Meredith Little, MPH, Shangbang Rao, PhD, Joseph Woolery, PharmD, Thomas Manley, MD, Lorenz Trümper, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 997.
https://doi.org/10.1182/blood-2018-99-110563
Published: 2018
Journal Articles

Real World Prevalence of Diagnostic Revision Among Patients with Peripheral T-Cell Lymphomas (PTCL) in the US: Results of an Administrative Claims and Electronic Medical Record Analyses

Joseph Feliciano, PharmD, Machaon Bonafede, Donna McMorrow, Julie Park, Julie Lisano, Thomas Manley, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1633.
https://doi.org/10.1182/blood-2018-99-117104
Published: 2018
Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Alison J. Moskowitz, MD, Armando Santoro, MD, Giuseppe Gritti, Pauline Brice, MD, David Cunningham, Paul Barr, MD, Justin Kline, MD, John Kuruvilla, MD, Nathalie A Johnson, MDPhD, Neha Mehta-Shah, MD, Thomas Manley, MD, Manish Sharma, Stephen Francis, Joseph Cohen, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1691.
https://doi.org/10.1182/blood-2018-99-112069
Published: 2018